GRI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["- Not a good buy right now: price is below key support (S1 2.65) with a clearly bearish moving-average stack (SMA_200 > SMA_20 > SMA_5), signaling the downtrend is still in control.", "- No Intellectia edge today (no AI Stock Picker / no SwingMax), so there\u2019s no proprietary timing support for an aggressive entry.", "- Near-term odds skew slightly negative (pattern analog suggests -0.78% next day and -1.43% next week), which is unfavorable for an impatient buyer.", "- The most immediate catalyst is financing/public offering planning, which typically pressures micro-cap biotech shares even when clinical news is positive."]
["- Trend: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), consistent with sustained downside momentum.", "- RSI (6): 10.976 = extremely oversold, which can spark bounces, but oversold alone is not a buy signal when trend and financing overhang are negative.", "- MACD: Histogram 0.678 above zero but positively contracting, suggesting upside momentum is fading rather than accelerating.", "- Support/Resistance: Current ~2.48 is below S1 (2.65), indicating a breakdown; next notable support is S2 (1.602). Pivot resistance is far above at 4.346.", "- Intellectia Proprietary Trading Signals", "- AI Stock Picker: no signal on given stock today.", "- SwingMax: No signal on given stock recently."]
["- Phase 2a readout: GRI-0621 showed significant modulation of genes related to lung injury; reported positive Phase 2 data with promising efficacy/safety signals for further development.", "- Broader theme/tailwind: ongoing advancements in gene-therapy and lung-injury treatment research may support interest in the space."]
["- Financing/dilution overhang: raised $6.5M in Jan 2026 and is planning an ~$8M public offering, which can cap rallies and pressure the share price.", "- Profitability not improving: FY2025 net loss referenced; latest quarter still shows meaningful losses and no revenue.", "- Price action remains weak despite \u201cpositive data\u201d headlines (e.g., a noted ~20% share drop around the Phase 2 update), implying skeptical market sentiment."]
["- Latest reported quarter: 2025/Q4.", "- Revenue: 0 (no commercial revenue; YoY change effectively 0%).", "- Net income: -2,659,000 (loss widened YoY by ~31.1%).", "- EPS: reported as -3410.36 (large negative; likely distorted by capital structure/share count dynamics\u2014directionally still reflects heavy losses).", "- Overall: loss-making with no revenue base, increasing reliance on external funding."]
["- No analyst rating or price target change data was provided, so a current Wall Street consensus/pros-vs-cons view cannot be confirmed from the dataset.", "- Practical read-through from available signals: financing dependence and weak tape are the dominant \u201ccons,\u201d while Phase 2 progress is the key \u201cpro.\u201d"]
